Cancer risk in children and young adults born preterm: A systematic review and meta-analysis

Katryn Paquette¹, Hallie Coltin², Ariane Boivin³, Devendra Amre¹, Anne-Monique Nuyt¹, Thuy Mai Luu¹*

¹ Department of Pediatrics, Sainte-Justine University Hospital and Research Center, University of Montreal, Montreal, Quebec, Canada, ² Department of Pediatrics, Children’s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada, ³ CEGEP Garneau, Quebec City, Quebec, Canada

*thuy.mai.luu@umontreal.ca

Abstract

Introduction

Risk of developing a malignancy when born premature is unknown. We hypothesised that risk of certain cancers might be increased in youth born preterm versus term. We therefore performed a systematic review and meta-analysis to evaluate the incidence of malignancy in the context of preterm birth, according to various cancer types.

Methods

The study was designed per MOOSE and PRISMA guidelines. Articles were identified through November 2015. Observational studies exploring the association between childhood malignancy and birth characteristics were included. Of the 1658 records identified, 109 full text articles were evaluated for eligibility. Random effects meta-analyses were conducted on 10/26 studies retained; 95% confidence intervals were computed and adjusted following sensitivity analysis. Publication bias was evaluated using funnel plots, Begg’s and Egger’s tests.

Results

No differences in risk of primary central nervous system tumor [OR 1.05; 95% CI 0.93–1.17, 5 studies, 580 cases] and neuroblastoma [OR 1.09; 95% CI 0.90–1.32, 5 studies, 211 cases] were observed in individuals born <37 versus ≥37 weeks’ gestation. Preterm birth was consistently associated with hepatoblastoma [ORs 3.12 (95% CI 2.32–4.20), 1.52 (95% CI 1.1–2.1), 1.82 (95% CI 1.01–3.26), and 2.65 (95% CI 1.98–3.55)], but not leukemia, astrocytoma, ependymoma, medulloblastoma, lymphoma, nephroblastoma, rhabdomyosarcoma, retinoblastoma or thyroid cancer.

Conclusions

Children born premature may be at increased risk for hepatoblastoma but there is no strong evidence of an increased risk of primary central nervous system tumours or neuroblastoma.
There is insufficient evidence to conclude whether prematurity modulates the risk of other childhood cancers.

**Introduction**

Perinatal characteristics have been described as independent risk factors for cancer development. An estimated 10% of neonates are born preterm; more than 95% of these babies live[1]. In preterm newborns, significant insults result from the exposure of immature antioxidant defence systems to pro-oxidants, such as oxygen, UV light, parenteral nutrition, and plastic derivatives[2]. Oxidative stress has been established in the causal pathway of two common short-term sequelae of prematurity, bronchopulmonary dysplasia and retinopathy of prematurity, as well as death[3–5].

Experimental data suggest that enduring impacts of early oxidative stress exposure include premature arrest of cellular proliferation, rapid tissue differentiation, oxidative DNA damage, and impaired DNA repair[6–8]. As a result, preterm birth might increase the risk of cancer development. Researchers have attempted to evaluate the impact of perinatal factors on cancer development, but have been unable to isolate for the effects of gestational age (GA) with sufficient power to risk stratify for prematurity. As a result, the effect of low birth weight and intrauterine growth restriction on the risk of cancer are the focus of the majority of published review papers. Two recent meta-analyses suggested that prematurity augments the risk of nephroblastoma and testicular cancers, but were hampered by publication bias and divergent methodologies within the observational studies used in their summary effects[9, 10]. Moreover, these cancers comprise <6% of all pediatric oncologic cases[11]. The risk afforded by prematurity for developing childhood cancer thus remains unclear.

We therefore conducted a systematic review and meta-analysis of observational studies to determine whether preterm birth was associated with increased incidence of childhood malignancy, according to cancer type. We hypothesised that the risk of certain cancers may be increased in children and young adults born preterm versus term.

**Materials and methods**

We designed the study per MOOSE and PRISMA guidelines. Articles were identified from EMBASE, Medline (including In-Process & Other Non-Indexed Citations), and all EBM Reviews (Cochrane DSR, ACP Journal Club, DARE, CCTR, CMR, HTA, and NHSEED) by the principal investigator (KP) from the inception date of each resource to November 1, 2015. Expandable terms were used as MESH headings and keywords: cancer, malignan*, leukemia or leukaemia, lymphoma, tumor or tumour, “blastoma, *sarcoma, *carcinoma”. Any of these terms were combined with ((prem* or preterm) and birth)) and (infant or child* or juvenile). The search was limited to children (0–21 years) and writings in English or French. Reference lists were searched for additional titles (S1 Table). Authors were not contacted for unpublished work they may be aware of. Search was designed by KP in association with institution’s librarians.

Regarding article selection, original observational studies conducted on humans were considered if they reported the rate of childhood cancers in the context of GA at birth. Articles were excluded if the specific GA could not be ascertained, the definition of prematurity was not <37weeks GA, the method for cancer diagnosis was not stated or was not an accepted standard at the time of diagnosis, if there was a lack of term-born controls, and if all the
reported cases were included in another study from our data set. Articles pertaining to testicular tumours were excluded, as a recent meta-analysis examined their association with GA[10]. All titles and abstracts were independently reviewed for eligibility by two reviewers (AB, KP) who then assessed full-text articles per selection criteria. Disagreements were resolved by consensus. Data extraction and quality assessment were performed by three independent individuals (AB, HC, KP). The quality of each article was objectively appraised using the Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis.

Data was extracted by three independent authors (KP, HC, AB) for study methodology, publication date, cancer type, country(ies) included, year(s) of diagnosis, age at time of diagnosis, method of diagnosis, study population, matching criteria, confounders, risk estimates by GA, and the use of adjustment models. Two authors were contacted for additional information. Although these authors responded to our queries, the details that we requested were not available. Extracted data were entered into Microsoft Excel Version 1704 (Microsoft, Redmond, WA, USA). The data underwent a final review by two authors (KP, DA) prior to analysis to assess and correct for discrepancies.

Meta-analysis was performed in Stata/IC 12.1 (Stata Corp, College Station, TX, USA). Analyses were performed using odds ratios (ORs) per unadjusted risk estimates reported in the primary publications for birth at < vs ≥37 weeks GA. In the absence of unadjusted risk estimates for these dichotomized GA categories, they were calculated from frequency tables provided in the manuscript or by personal correspondence with study investigators. Unadjusted values were used to mitigate the heterogeneity induced by combining risks adjusted for different characteristics and to allow for a larger sample size (multiple articles retained did not have adjusted risk estimates). However, repeating analyses using adjusted risk estimates when available altered neither the magnitude nor the direction of the summary effects.

To account for inter-study variability and increase meta-analysis power, outcomes with five or more studies were subjected to random effects meta-analyses. Random effects meta-analyses were used due to the inherent heterogeneity present between observational studies. Outcomes with four or fewer studies were assessed from a qualitative perspective only. Due to its rare occurrence, pooled analyses stratifying cancer risks by the degree of prematurity were not performed. Heterogeneity was evaluated using the I² statistic. Finally, publication bias was evaluated by inspection of funnel plots, Egger’s and Beggs’ tests.

Results

The database search identified 1,658 records; 193 remained after screening their titles. Of these, 84 studies were excluded after reading their abstracts. We evaluated 109 full text articles for eligibility, 26 were retained for the qualitative synthesis, of which 10 were eligible for meta-analysis (Fig 1). We excluded 29 articles with overlapping data sets. When multiple studies had overlapping populations, we included the study, or groups of studies, with the largest sample size. Of the 26 studies retained, 13 were of good quality (NOS 4–6 stars)[12–24] and 13 were excellent (7–9 stars)[25–37]. See Table 1 for study details. See Table 2 for summary of non-meta-analyzed cancer-specific data.

Leukemia

Overall, six studies reported on leukemias, including one from Oksuzyan et al [31], which did not exclude individuals with trisomy 21, a major risk factor for leukemias in general. Indeed, Oksuzyan et al were the only authors to find difference in leukemias in preterm versus full-term born individuals (see below).
Four manuscripts combining 1,134 patients born preterm were retained to evaluate the relationship between gestational age and ALL [30, 31, 35, 36]. The risk of ALL was similar between studies; these studies did not suggest an association between ALL and preterm birth (Table 2). Data were not meta-analyzed due to population overlap.

Three studies compared AML in individuals born at <37 versus ≥37 weeks, totalling 245 cases [30, 31, 35] (Table 2). Two studies highlighted no difference in the risk of AML when born preterm, while the study by Oksuzyan et al suggested an increased risk (OR 1.45; 95% CI 1.08–1.95)[31]. No summary effects were performed due to the limited sample of studies.

Three studies assessed risks of any leukemia following preterm birth [20, 21, 31] (Table 2). These studies yielded 937 exposed cases with an association between preterm birth and leukemia only identified in Oksuzyan et al (OR 1.14; 95% CI 1.00–1.28)[31].
### Table 1. Studies retained for the meta-analysis and systematic review.

#### Studies Retained for Meta-Analysis

| Author, year | NOS | Study Design | Data Source | Country ± State | Years of Diagnosis | Cancer Type | Age at Diagnosis |
|--------------|-----|--------------|-------------|-----------------|-------------------|-------------|-----------------|
| Emerson, 1991 | 7   | Case control | Registry    | USA: WA<sup>b</sup> | 1974–1986 | CNS<sup>c</sup> tumors | ≤10 years |
| Buck, 2001    | 5   | Case control | Registry, Medical Records Phone Interview | USA: NY<sup>d</sup> | 1976–1987 | Neuroblastoma | ≤5 years |
| Fear, 2001    | 4   | Case control | Medical Records, Phone Interview | USA, Canada | 1992–1994 | Neuroblastoma | ≤18 years |
| Hamrick, 2001 | 6   | Case control | Registry, Phone Interview | Sweden | 1973–1995 | Neuroblastoma | ≤21 years |
| Bluhm, 2008   | 6   | Nested Case control | Registry, Phone Interview | France | 2003–2004 | Neuroblastoma | ≤14 years |
| Munzer, 2008  | 5   | Case control | Medical Records, Phone Interview, Interview at diagnosis | USA: CA<sup>e</sup>, MN<sup>f</sup>, NY<sup>g</sup>, TX<sup>h</sup>, WA<sup>i</sup> | 1980–2004 | All common malignancies | 28 days–14 years<sup>k</sup> |
| Schmidt, 2010 | 7   | Case control | Registry | Denmark, Finland, Norway, Sweden | 1985–2006 | CNS tumors | ≤14 years |
| Sprehe, 2010  | 6   | Case control | Registry | USA: TX | 1995–2003 | Cancers, leukemias, CNS tumors | ≤4 years |
| Spector, 2009 | 7   | Case control | Registry | USA: CA<sup>e</sup>, MN<sup>f</sup>, NY<sup>g</sup>, TX<sup>h</sup>, WA<sup>i</sup> | 1980–2004 | All common malignancies | 28 days–14 years<sup>k</sup> |
| Jepsen, 2004  | 6   | Case control | Registry | Denmark | 1973–1993 | Wilms Tumor | ≤14 years |
| Podvin, 2006  | 6   | Case control | Registry | USA: WA | 1981–2008 | Leukemia–all combined | ≤19 years |
| Johnson, 2011 | 7   | Case control | Registry | USA: CA, MN, NY, TX, WA<sup>i</sup> | 1980–2004 | All carcinomas | 28 days–14 years |
| Schüz, 2011   | 7   | Case control | Registry | Denmark, Finland, Norway, Sweden | 1985–2006 | Wilms tumor | ≤14 years |
| Crump, 2012   | 8   | Cohort | Registry | Sweden | 1973–2009 | Hodgkin Lymphoma | 1–37 years<sup>l</sup> |
| Crump, 2012   | 8   | Cohort | Registry | Sweden | 1973–2009 | Non-Hodgkin Lymphoma | 0–37 years<sup>l</sup> |
| de Fine Licht, 2012 | 7 | Case control | Registry | Denmark, Finland, Norway, Sweden | 1985–2006 | Hepatoblastoma | ≤14 years |
| Heck, 2012    | 6   | Case control | Registry | USA: CA<sup>e</sup>, MN<sup>f</sup>, NY<sup>g</sup>, TX<sup>h</sup>, WA<sup>i</sup> | 1988–2007 | Retinoblastoma | ≤5 years |
| Oksuzyan, 2012| 7   | Case control | Registry | USA: CA<sup>e</sup>, MN<sup>f</sup>, NY<sup>g</sup>, TX<sup>h</sup>, WA<sup>i</sup> | 1988–2008 | Leukemias | ≤15 years |
| Puumala, 2012 | 6   | Case control | Registry, Phone Interview | USA | 2000–2008 | Hepatoblastoma | ≤5 years |
| Heck, 2013    | 6   | Case control | Registry | USA: CA<sup>e</sup>, MN<sup>f</sup>, NY<sup>g</sup>, TX<sup>h</sup>, WA<sup>i</sup> | 1988–2007 | Hepatoblastoma | ≤5 years |
| Shrestha, 2013| 6   | Case control | Registry | USA: CA<sup>e</sup>, MN<sup>f</sup>, NY<sup>g</sup>, TX<sup>h</sup>, WA<sup>i</sup> | 1988–2008 | Rhabdomyosarcoma | ≤5 years |
| Crump, 2014   | 8   | Cohort | Registry | Sweden | 1973–2009 | Wilms tumor | ? |
| Marcotte, 2014| 6   | Case control | Registry | USA: CA<sup>e</sup>, MN<sup>f</sup>, NY<sup>g</sup>, TX<sup>h</sup>, WA<sup>i</sup> | 1988–2007 | Lymphomas | ≤5 years |

(Continued)
Primary CNS tumors

Six studies evaluated the association between premature birth and primary CNS tumors [14, 21, 29, 32, 33, 35]. These were case control studies with minimal population overlap; most included children from birth to adolescence.

Five manuscripts reported ORs for all primary CNS tumors combined [14, 21, 29, 32, 33]. All five studies were case control by design without overlap in study region. There was, however, clinical heterogeneity in the underlying study designs: Emerson et al, Shmidt et al and Oksuzyan et al had no exclusion criteria, while Fear et al excluded children born with physical or chromosomal abnormalities and Sprehe et al excluded children born of multiple gestation pregnancies (i.e. not singletons). Furthermore, the age at diagnosis of children included in the studies varied between $\leq 4$ years and $\leq 15$ years of age. Combining their data yielded 580 cases and a summary OR of 1.05 (95% CI 0.93–1.17) in those born at $<37$ versus $\geq 37$ weeks (Fig 2).

Despite the clinical differences in study inclusion criteria, no heterogeneity ($I^2 0\%$) or publication bias (S1 Fig) were noted in the summary effects.

Risk assessments for individual primary CNS tumors were reported by three studies [29, 32, 35]. There was no significant difference in risk for astrocytoma or medulloblastoma (Table 2). Fifty cases of ependymoma in individuals born preterm were reported yielding ORs of 5.5 (95% CI 1.0–29.5)[29], 0.90 (95% CI 0.60–1.90)[35], 0.73 (0.41–1.29)[32]. The study by Emerson et al, the only study to suggest that birth at $<37$ weeks was associated with an increased risk of ependymoma when compared to birth at $\geq 37$ weeks, was the oldest study in this set, including children diagnosed between 1974 and 1986. Spector et al and Oksuzyan et al recruited from the 1980s through to the 2000s. Furthermore, Emerson et al included children diagnosed at $\leq 10$ years of age, whereas latter two teams recruited adolescents up to 14 and 16 years of age respectively. All three studies were of American youth.

Neuroblastoma

Five articles were retained pertaining to neuroblastoma [12, 13, 15, 19, 35]. Of the 211 cases among children born preterm, 87% were North American. The studies’ background methodologies were homogeneous: case control designs, no exclusion criteria except for Spector et al (trisomy 21), and most recruiting patients into adolescence. Risk of neuroblastoma was not
Table 2. Cancer-specific data not amenable to meta-analysis.

| Author, year | Cases Born < 37 Weeks | Cases Born ≥ 37 Weeks | Controls Born < 37 Weeks | Controls Born ≥ 37 Weeks | Odds Ratio (95% Confidence Interval) |
|--------------|-----------------------|-----------------------|-------------------------|-------------------------|--------------------------------------|
| Acute Lymphocytic Leukemia | | | |
| Hjalgrim, 2004 | 186 | 1,631 | 846 | 7,981 | 1.08 (0.91–1.27) |
| Spector, 2009* | 371 | 4,199 | 4,404 | 50,858 | 1.02 (0.91–1.14) |
| Oksuzyan, 2012 | 466 | 4,005 | 441 | 3,987 | 1.05 (0.92–1.21) |
| Crump, 2015 | 111 | 1,849 | 205,387 | 3,362,946 | 0.98 (0.81–1.19) |
| Acute Myeloid Leukemia | | | |
| Hjalgrim, 2004 | 26 | 254 | 124 | 1,248 | 1.03 (0.66–1.61) |
| Spector, 2009* | 611 | 758 | 4,404 | 50,858 | 0.93 (0.71–1.21) |
| Oksuzyan, 2012 | 120 | 681 | 87 | 717 | 1.45 (1.08–1.95) |
| All Leukemias Combined | | | |
| Podvin, 2006 | 42 | 535 | 437 | 5,279 | 0.96 (0.69–1.34) |
| Sprehe, 2010 | 253 | 2090 | 1,301 | 10,982 | 0.92 (0.73–1.16) |
| Oksuzyan, 2012 | 642 | 5145 | 573 | 5215 | 1.14 (1.00–1.28) |
| Astrocytoma | | | |
| Emerson, 1991 | 5 | NR | 35 | NR | 0.70 (0.20–1.70) |
| Spector, 2009* | 108 | 1495 | 4,404 | 50,858 | 0.78 (0.58–1.08) |
| Oksuzyan, 2013 | 111 | 1176 | 132 | 1,157 | 0.83 (0.63–1.08) |
| Ependymoma | | | |
| Emerson, 1991 | 3 | NR | 3 | NR | 5.5 (1.0–29.5) |
| Spector, 2009* | 24 | 355 | 4,404 | 50,858 | 0.90 (0.60–1.90) |
| Oksuzyan, 2013 | 23 | 237 | 30 | 228 | 0.73 (0.41–1.29) |
| Medulloblastoma | | | |
| Emerson, 1991 | 33 | NR | 13 | NR | 1.2 (0.30–4.7) |
| Oksuzyan, 2013 | 44 | 324 | 39 | 330 | 1.16 (0.73–1.84) |
| Nephroblastoma | | | |
| Jepsen, 2004 | 7 | 119 | NR | NR | 1.05 (0.43–2.56) |
| Spector, 2009* | 120 | 1023 | 4,404 | 50,858 | 1.35 (1.19–1.64) |
| Schütz, 2011 | 39 | 627 | 148 | 3017 | 1.27 (0.88–1.82) |
| Crump, 2014 | 31 | 376 | 206,813 | 1,503,188 | 1.22 (0.85–1.76) |
| Non-Hodgkin Lymphoma | | | |
| Spector, 2009* | 47 | 522 | 4,404 | 50,858 | 1.04 (0.77–1.40) |
| Crump, 2012 | 54 | 882 | 206,790 | 3,363,748 | 1.00 (0.76–1.31) |
| Marcotte, 2014 | 14 | 156 | 20,118 | 176,842 | 0.78 (0.45–1.34) |
| Hodgkin Lymphoma | | | |
| Spector, 2009* | 34 | 431 | 4,404 | 50,858 | 0.91 (0.64–1.29) |
| Crump, 2012 | 54 | 871 | 206,790 | 3,363,841 | 0.98 (0.75–1.30) |
| Marcotte, 2014 | 1 | 55 | 20,118 | 176,842 | - |
| All Lymphomas Combined | | | |
| Spector, 2009* | 104 | 1,153 | 4,404 | 50,858 | 1.04 (0.85–1.28) |
| Marcotte, 2014 | 45 | 410 | 20,118 | 176,842 | 0.95 (0.70–1.29) |
| Hepatoblastoma | | | |
| Spector, 2009* | 56 | 207 | 4,404 | 50,858 | 3.12 (2.32–4.20) |
| Puumala, 2012 | 87 | 294 | 119 | 265 | 1.52 (1.1–2.1) |
| de Fine Licht, 2012 | 17 | 87 | 49 | 650 | 1.82 (1.01–3.26) |
| Heck, 2013 | 59 | 189 | 21,749 | 184,715 | 2.65 (1.98–3.55) |

Rhabdomyosarcoma

(Continued)
### Table 2. (Continued)

| Author, year   | Cases Born < 37 Weeks | Cases Born ≥ 37 Weeks | Controls Born < 37 Weeks | Controls Born ≥ 37 Weeks | Odds Ratio (95% Confidence Interval) |
|----------------|-----------------------|-----------------------|--------------------------|--------------------------|--------------------------------------|
| Spector, 2009* | 42                    | 522                   | 4,404                    | 50,858                   | 0.93 (0.8–1.27)                      |
| Shrestha, 2013 | 36                    | 309                   | 20,099                   | 176,647                  | 1.04 (0.73–1.46)                     |
|                |                       |                       |                          |                          | **Retinoblastoma**                   |
| Spector, 2009* | 64                    | 603                   | 4,404                    | 50,858                   | 1.23 (0.95–1.58)                     |
| Heck, 2012     | 61                    | 548                   | 21,323                   | 187,728                  | 1.02 (0.77–1.34)                     |
|                |                       |                       |                          |                          | **Thyroid Cancer**                   |
| Johnson, 2011  | 18                    | 123                   | NR                       | NR                       | 1.87 (1.07–3.27)                     |

* Spector et al recruited 4,404 preterm-born and 50,858 term-born children who were cancer free between 28 days and 15 years of age; these children represented the preterm-born controls for all cancers studied.

§ Not reported

https://doi.org/10.1371/journal.pone.0210366.t002
increased in those born <37 versus ≥37 weeks GA (OR 1.09; 95% CI 0.9–1.32). For the summary effect, heterogeneity was minimal with $I^2$ 12.5% (Fig 3). No publication bias was noted (S2 Fig).

**Nephroblastoma**

Four studies remained for the analysis of nephroblastoma risk [18, 25, 34, 35] (Table 2). Two were case control by design, all were registry based, and 61% of the 197 cases were from the United States. Due to significant case duplication and the small sample size, summary effects were not calculated. Only Spector et al found significant difference in nephroblastoma in preterm versus full-term born individuals (OR 1.35; 95% CI 1.19–1.64)[35].

**Lymphoma**

Four heterogeneous studies evaluating the development of lymphoma were retained[22, 26, 27, 35]. Indeed, both studies by Crump et al were cohorts that included persons ≤36 years old. Spector et al conducted a case control study recruiting children 28 days to 14 years old. Finally, Marcotte et al performed a case control study recruiting preschoolers ≤4 years old. Due to the heterogeneity in study methodology and limited sample size, no summary effects were
calculated. Non-Hodgkin lymphomas, Hodgkin lymphomas, or any lymphomas were not significantly different in preterm versus full-term born individuals (Table 2).

**Hepatoblastoma**

Four case control studies measured the association between prematurity and hepatoblastoma [17, 23, 28, 35]. Of the 219 cases among children born preterm, 92% were North American. Indeed, all studies but the one by de Fine Licht et al originated from the United States. All studies suggested that hepatoblastoma was more common following preterm versus full-term birth with ORs of 3.12 (95% CI 2.32–4.20)[35], 1.52 (95% CI 1.1–2.1)[23], 1.82 (95% CI 1.01–3.26) [28], and 2.65 (95% CI 1.98–3.55)[17].

**Other solid organ cancers**

We found a small sample of studies on other solid organ cancers. Two studies reported findings for rhabdomyosarcoma[24, 35]. Spector et al included ≤14-year-olds in five states, while Shrestha et al recruited Californian children less than five years of age from 1988–2008. There was a 10-year overlap between studies. Seventy-eight cases were reported with ORs of 0.93 (95% CI 0.8–1.27)[35] and 1.04 (95% CI 0.73–1.46)[24] respectively.

Two registry-based case control studies with significant sample duplication evaluated the impact of prematurity on retinoblastoma [16, 35]. Heck et al reported 61 exposed Californian cases from 1988–2007, with an OR of 1.02 (95% CI 0.77–1.34) in the event of preterm birth. Spector et al found 64 cases in five states, including California (1988–1997), with an OR of 1.23 (95% CI 0.95–1.58).

Johnson et al described the prevalence of thyroid cancer in U.S. children. They reported 18 cases in individuals born preterm with OR of 1.87 (95% CI 1.07–3.27)[37].

**Discussion**

Our results suggest that there is no significant difference in the risk of primary CNS tumors or neuroblastoma in those born preterm versus not preterm. Data was insufficient to conclude whether there is an impact on the development of leukemias, astrocytomas, ependymomas, medulloblastomas, nephroblastoma, lymphomas, rhabdomyosarcoma, retinoblastoma or thyroid cancer when born prematurely. Preterm birth may increase the risk of hepatoblastoma. Our results echo the findings of most published studies addressing this question.

A recent meta-analysis evaluating the impact of preterm birth on childhood leukemias also noted no increase in the risk of ALL or all leukemias combined, but found a modest increase in the risk of AML[38]. However, the studies included for summary effects were older and numerous samples were entirely duplicated. Conversely, Crump et al updated reports of AML cases in Sweden between 1973–2010[39]; 14 cases occurred in persons born preterm for an OR of 0.76 (95% CI 0.44–1.3), again shifting the balance of risk to one of neutrality.

Our results are also concordant with an updated case control study of adolescent CNS tumors in Scandinavia[40]. Among children born at <37 vs ≥37 weeks, the odds of developing a primary CNS tumor or astrocytoma were 1.04 (95% CI 0.48–2.3) and 0.62 (95% CI 0.19–1.99) respectively.

Unlike a 2010 meta-analysis[9], our data do not suggest that preterm birth increases the risk of nephroblastoma. We did not perform summary effects due to the limited sample size and high frequency of case duplication. Indeed, more than 75% of the weight for summary effects in the aforementioned manuscript arose from studies with methodological limitations: two defined preterm birth as <38 weeks, one did not define preterm birth. Since these three
studies had the largest and most significant ORs [1.28–1.88 (95% CIs 0.94–1.27, 1.74–2.78)], the overall cancer risk was over-estimated.

Cancer development requires a complex mix of cellular dysregulation and aberrant immune surveillance within the host to enable significant proliferation of a malignant line. Mechanisms which have been implicated in childhood cancer include abnormal growth factor signaling pathways, ionizing radiation, oxidative stress, environmental toxin exposure, viral infection, and underlying genetic mutations or syndromes [41–43]. Although preterm neonates are confronted by many of these adverse elements in utero and then in the NICU, there is also evidence that ex-utero organogenesis results in reduced cellular endowment in many developing organs [44, 45]. A decreased pool for cellular proliferation may help counter pro-oncogenic factors, helping to mitigate the malignant potential otherwise introduced by premature birth.

It is biologically plausible that the liver remains a vulnerable organ with increased susceptibility to cancer when exposed to preterm birth. The newborn liver is a highly metabolic organ responsible for numerous endocrine and exocrine functions, while undergoing maturation[46, 47]. This organ is exposed to repeated stressors via low lying umbilical venous lines, parenteral nutrition and its peroxide load, the stress of polypharmacy, and the first pass effect. The first pass effect is significant, whereby the liver serves as a gateway, metabolizing ingested compounds prior to their entering the systemic circulation. Furthermore, potential hepatocarcinogens such as the plasticizer di-(2-ethylhexyl)phthalate[48], which has been associated with liver cancer in animal models, may also be present in the nursery causing exposure during infancy.

Our study’s findings carry strong internal and external validity due to rigorous methodology, the inclusion of high-quality studies, minimization of duplicated populations, and computation of risk effects with a precise and accurate definition of preterm birth. The studies we included spanned multiple decades and 75% recruited cases into the 2000s, reducing the population bias inherent to earlier meta-analysis. Older manuscripts included individuals born primarily before 1990, many before 1980, when the incidence of premature birth was less and fewer preterm newborns survived [1, 49], potentially artificially lowering effect estimates for the risk of cancer.

Our use of registry-based studies limits introduction of recall bias, but may be a source of selection bias. All studies retained in our project used population-based registries, which are well established in the United States and Scandinavia. Hence, most cases were Caucasian, and all were from developed nations. Moreover, the multifactorial nature of cancer development might translate into requiring a larger sample size to detect a change in disease risk. Thus, type II error may be present, despite our performing summary analysis when at least 200 combined cases were reported.

The limited sample sizes obtained for the occurrence of cancer in individuals born preterm induces another potential source of type II error. Indeed, the occurrence of malignancy among those born prior to 37 weeks gestation was rare, with hundreds to thousands of cases of the most common cancers in exposed individuals, despite millions of subjects being included in the combined studies for these cancers. Consequently, individual studies were under-powered to present the risk of cancer by degree of prematurity, as were we. For less common cancers, the order of magnitude of exposed cases was tens to hundreds, precluding quantitative analyses of these malignancies. Although the limited sample size is a limitation in determining the risk of cancer among those born preterm vs term, it may also be interpreted as a reassuring finding. If we assume that 10% of individuals are born preterm and that studies spanning decades yielded so few cases, then the absolute risk of cancer among persons born preterm is likely very small.
As previously mentioned, multiple studies have found increased risk of cancer among those born with low birth weight, including hepatoblastoma. Since birth weight varies as a function of GA, comparing low birth weight vs. normal birth weight infants does not discriminate between the impact of potential intrauterine growth restriction and GA on cancer development. Differentiating the effect of birthweight and GA on childhood cancer is challenging due to the limited data available. Ideally, we would compare the risk of hepatoblastoma among infants born weighing less than 10th percentile for GA with those born at an appropriate weight for GA as a function of completed weeks of gestation at birth.

Our study suggests that prematurity has no impact on the incidence of most childhood cancers. Although the risk of hepatoblastoma may be increased, its occurrence is so rare that the National Cancer Institute’s surveillance program has been unable to calculate an incidence rate since 1999, when there were 5 to 10.5 cases per million children below five years of age[50, 51]. This decrease in cancer incidence is occurring despite increasing survival rates of preterm neonates. Furthermore, since parenteral nutrition has improved, and neonatal providers are more aggressive with enteral feed introduction, it is anticipated that the rate of hepatoblastoma in individuals born preterm may decrease.

Conclusion
Preterm birth does not appear to be associated with an increased risk of most childhood cancers. Birth prior to 37 weeks GA may increase the risk of hepatoblastoma. Ongoing surveillance of aging prospective cohorts would be beneficial to provide insight into cancer risks in the aging population of individuals born preterm.

Supporting information
S1 Table. Search strategy.
(DOCX)

S1 Fig. Funnel plot for the ascertainment of publication bias in studies of all primary central nervous system tumors combined.
(TIFF)

S2 Fig. Funnel plot for the ascertainment of publication bias in studies of neuroblastoma.
(TIFF)

S1 File. MOOSE checklist.
(DOC)

S2 File. PRISMA checklist.
(DOC)

Acknowledgments
The authors would like to thank Sarah Paquin, PhD (Laval University, Quebec City, Quebec, Canada) for her contributions to the data extraction for this analysis.

Author Contributions
Conceptualization: Katryn Paquette, Ariane Boivin, Anne-Monique Nuyt, Thuy Mai Luu.

Data curation: Katryn Paquette, Hallie Coltin, Ariane Boivin.

Formal analysis: Katryn Paquette, Devendra Amre.
Methodology: Katryn Paquette, Devendra Amre, Anne-Monique Nuyt, Thuy Mai Luu.

Supervision: Anne-Monique Nuyt, Thuy Mai Luu.

Validation: Thuy Mai Luu.

Writing – original draft: Katryn Paquette.

Writing – review & editing: Katryn Paquette, Hallie Coltin, Ariane Boivin, Devendra Amre, Anne-Monique Nuyt, Thuy Mai Luu.

References

1. March of Dimes, PMNCH, Save the Children, WHO. Born Too Soon: The Global Action Report on Preterm Birth. Geneva; World Health Organisation 2012.

2. Nuyt AM, Lavoie JC, Mohamed I, Paquette K, Luu TM. Adult Consequences of Extremely Preterm Birth: Cardiovascular and Metabolic Diseases Risk Factors, Mechanisms, and Prevention Avenues. Clin Perinatol. 2017; 44(2):315–32. https://doi.org/10.1016/j.clp.2017.01.010 PMID: 28477663

3. Chessex P, Watson C, Kaczala GW, Rouleau T, Lavoie ME, Friel J, et al. Determinants of oxidant stress in extremely low birth weight premature infants. Free radical biology & medicine. 2010; 49(9):1380–6.

4. Mohamed I, Elremaly W, Rouleau T, Lavoie JC. Ascorbylperoxide Contaminating Parenteral Nutrition Is Associated With Bronchopulmonary Dysplasia or Death in Extremely Preterm Infants. JPEN J Parenter Enteral Nutr. 2016.

5. Stone WL, Shah D, Hollinger SM. Retinopathy of prematurity: an oxidative stress neonatal disease. Front Biosci (Landmark Ed). 2016; 21:165–77.

6. Luyckx VA, Compton CA, Simmen T, Mueller TF. Accelerated senescence in kidneys of low-birth-weight rats after catch-up growth. Am J Physiol Renal Physiol. 2009; 297(6):F1697–705. https://doi.org/10.1152/ajprenal.00462.2009 PMID: 19828676

7. Sutherland MR, Beland C, Lukaszewski MA, Cliament A, Bertagnolli M, Nuyt AM. Age- and sex-related changes in rat renal function and pathology following neonatal hyperoxia exposure. Physiol Rep. 2016; 4(15).

8. Tarry-Adkins JL, Martin-Gronert MS, Chen JH, Cripps RL, Ozanne SE. Maternal diet influences DNA damage, aortic telomere length, oxidative stress, and antioxidant defense capacity in rats. FASEB J. 2008; 22(6):2037–44. https://doi.org/10.1096/fj.07-099523 PMID: 18230683

9. Chu A, Heck JE, Ribeiro KB, Brennan P, Boffetta P, Buffler P, et al. Wilms’ tumour: a systematic review of risk factors and meta-analysis. Paediatr Perinat Epidemiol. 2010; 24(5):449–69. https://doi.org/10.1111/j.1365-3016.2010.01133.x PMID: 20670226

10. Cook MB, Akre O, Forman D, Madigan MP, Richiardi L, McGlynn KA. A systematic review and meta-analysis of perinatal variables in relation to the risk of testicular cancer—experiences of the son. Int J Epidemiol. 2010; 39(6):1605–18. https://doi.org/10.1093/ije/dyq120 PMID: 20660640

11. American Cancer Society. Cancer Facts & Figures 2016. Atlanta, Georgia; 2016.

12. Bluhm E, McNeil DE, Cnattingius S, Gridley G, El Ghormli L, Fraumeni JF Jr. Prenatal and perinatal risk factors for neuroblastoma. Int J Cancer. 2008; 123(12):2885–90. https://doi.org/10.1002/ijc.23847 PMID: 18798548

13. Buck GM, Michalek AM, Chen CJ, Nasca PC, Baptiste MS. Perinatal factors and risk of neuroblastoma. Paediatr Perinat Epidemiol. 2001; 15(1):47–53. PMID: 11237115

14. Fear NT, Roman E, Ansell P, Bull D. Malignant neoplasms of the brain during childhood: the role of prenatal and neonatal factors (United Kingdom). Cancer Causes Control. 2001; 12(5):443–9. PMID: 11545459

15. Hamrick SE, Olshan AF, Neglia JP, Pollock BH. Association of pregnancy history and birth characteristics with neuroblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. Paediatr Perinat Epidemiol. 2001; 15(4):328–37. PMID: 11703680

16. Heck JE, Lombardi CA, Meyers TJ, Cockburn M, Wilhelm M, Ritz B. Perinatal characteristics and retinoblastoma. Cancer Causes Control. 2012; 23(9):1567–75. https://doi.org/10.1007/s10552-012-0034-7 PMID: 22843021

17. Heck JE, Meyers TJ, Lombardi C, Park AS, Cockburn M, Reynolds P, et al. Case-control study of birth characteristics and the risk of hepatoblastoma. Cancer Epidemiol. 2013; 37(4):390–5. https://doi.org/10.1016/j.canep.2013.03.004 PMID: 23558166
18. Jepsen P, Olsen ML, Mellemkjæer L, Olsen JH, Sorensen HT. A registry-based study of gender, fetal growth, and risk of Wilms tumor. Pediatr Hematol Oncol. 2004; 21(5):435–9. https://doi.org/10.1080/0888001049057213 PMID: 15205087

19. Munzer C, Menegaux F, Lacour B, Valteau-Couanet D, Michon J, Coze C, et al. Birth-related characteristics, congenital malformation, maternal reproductive history and neuroblastoma: the ESCALE study (SFCE). Int J Cancer. 2008; 122(10):2315–21. https://doi.org/10.1002/ijc.23301 PMID: 18076072

20. Podvin D, Kuehn CM, Mueller BA, Williams M. Maternal and birth characteristics in relation to childhood leukaemia. Paediatr Perinat Epidemiol. 2006; 20(4):312–22. https://doi.org/10.1111/j.1365-3016.2006.00731.x PMID: 16879503

21. Sprehe MR, Barahmani N, Cao Y, Wang T, Forman MR, Bondy M, et al. Comparison of birth weight corrected for gestational age and birth weight alone in prediction of development of childhood leukemia and central nervous system tumors. Pediatr Blood Cancer. 2010; 54(2):242–9. https://doi.org/10.1002/pbc.22306 PMID: 19813253

22. Marcotte EL, Ritz B, Cockburn M, Clarke CA, Heck JE. Birth characteristics and risk of lymphoma in young children. Cancer Epidemiol. 2014; 38(1):48–55. https://doi.org/10.1016/j.canep.2013.11.005 PMID: 24345816

23. Puumala SE, Ross JA, Feusner JH, Tomlinson GE, Malogolowkin MH, Krailo MD, et al. Parental infertility, infertility treatment and hepatoblastoma: a report from the Children’s Oncology Group. Hum Reprod. 2012; 27(6):1649–56. https://doi.org/10.1038/humrep/des109 PMID: 22473396

24. Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal risk factors for Wilms tumor in a Swedish national cohort. European journal of epidemiology. 2014; 29(3):191–7. https://doi.org/10.1007/s10654-014-9880-9 PMID: 24510487

25. Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood. Am J Epidemiol. 2012; 176(12):1147–58. https://doi.org/10.1093/aje/kws122 PMID: 23171883

26. Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish national cohort study. J Natl Cancer Inst. 2012; 104(12):923–30. https://doi.org/10.1093/jnci/djs225 PMID: 22623506

27. Emerson JC, Malone KE, Daling JR, Starzyk P. Childhood brain tumor risk in relation to birth characteristics. J Clin Epidemiol. 1991; 44(11):1159–66. PMID: 1941011

28. Puumala SE, Ross JA, Feusner JH, Tomlinson GE, Malogolowkin MH, Krailo MD, et al. Parental infertility, infertility treatment and hepatoblastoma: a report from the Children’s Oncology Group. Hum Reprod. 2012; 27(6):1649–56. https://doi.org/10.1038/humrep/des109 PMID: 22473396

29. Oksuzyan S, Crespi CM, Cockburn M, Megezi G, Kheifets L. Birth weight and other perinatal characteristics and childhood leukemia in California. Cancer Epidemiol. 2012; 36(6):e359–65. https://doi.org/10.1016/j.canep.2012.08.002 PMID: 22926338

30. Oksuzyan S, Crespi CM, Cockburn M, Megezi G, Kheifets L. Birth weight and other perinatal factors and childhood CNS tumors: a case-control study in California. Cancer Epidemiol. 2013; 37(4):402–9. https://doi.org/10.1016/j.canep.2013.03.007 PMID: 23562044

31. Crump C, Sundquist J, Sieh W, Winkleby MA, Sundquist K. Perinatal risk factors for Wilms tumor in a Swedish national cohort. European journal of epidemiology. 2014; 29(3):191–7. https://doi.org/10.1007/s10654-014-9880-9 PMID: 24510487

32. Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal and family risk factors for Hodgkin lymphoma in childhood through young adulthood. Am J Epidemiol. 2012; 176(12):1147–58. https://doi.org/10.1093/aje/kws122 PMID: 23171883

33. Crump C, Sundquist K, Sieh W, Winkleby MA, Sundquist J. Perinatal and family risk factors for non-Hodgkin lymphoma in early life: a Swedish national cohort study. J Natl Cancer Inst. 2012; 104(12):923–30. https://doi.org/10.1093/jnci/djs225 PMID: 22623506

34. Emerson JC, Malone KE, Daling JR, Starzyk P. Childhood brain tumor risk in relation to birth characteristics. J Clin Epidemiol. 1991; 44(11):1159–66. PMID: 1941011

35. Oksuzyan S, Crespi CM, Cockburn M, Megezi G, Kheifets L. Birth weight and other perinatal characteristics and childhood leukemia in California. Cancer Epidemiol. 2012; 36(6):e359–65. https://doi.org/10.1016/j.canep.2012.08.002 PMID: 22926338

36. Crump C, Sundquist J, Sieh W, Winkleby MA, Sundquist K. Perinatal and familial risk factors for acute lymphoblastic leukemia in a Swedish national cohort. Cancer. 2015; 121(7):1040–7. https://doi.org/10.1002/cncr.29172 PMID: 25417823
37. Johnson KJ, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC, et al. Birth characteristics and childhood carcinomas. Br J Cancer. 2011; 105(9):1396–401. https://doi.org/10.1038/bjc.2011.359 PMID: 21915125

38. Huang QT, Gao YF, Zhong M, Yu YH. Preterm Birth and Subsequent Risk of Acute Childhood Leukemia: a Meta-Analysis of Observational Studies. Cell Physiol Biochem. 2016; 39(3):1229–38. https://doi.org/10.1159/000447828 PMID: 27595399

39. Crump C, Sundquist J, Sieh W, Winkleby MA, Sundquist K. Perinatal risk factors for acute myeloid leukemia. European journal of epidemiology. 2015; 30(12):1277–85. https://doi.org/10.1007/s10654-015-0063-0 PMID: 26113060

40. Vienneau D, Infanger D, Feychting M, Schuz J, Schmidt LS, Poulsen AH, et al. A multinational case-control study on childhood brain tumours, anthropogenic factors, birth characteristics and prenatal exposures: A validation of interview data. Cancer Epidemiol. 2016; 40:52–9. https://doi.org/10.1016/j.canep.2015.11.006 PMID: 26625087

41. Campisi J. Aging, cellular senescence, and cancer. Annu Rev Physiol. 2013; 75:685–705. https://doi.org/10.1146/annurev-physiol-030212-183653 PMID: 23140366

42. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med. 2009; 361(15):1475–85. https://doi.org/10.1056/NEJMra0804615 PMID: 19812404

43. Malkin D, Nichols KE, Zelley K, Schiffman JD. Predisposition to pediatric and hematologic cancers: a moving target. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2014:e44–55. https://doi.org/10.14694/EdBook_AM.2014.34.e44 PMID: 24857136

44. Koike K, Ikezumi Y, Tsuboi N, Kanzaki G, Haruhara K, Okabayashi Y, et al. Glomerular Density and Volume in Renal Biopsy Specimens of Children with Proteinuria Relative to Preterm Birth and Gestational Age. Clin J Am Soc Nephrol. 2017; 12(4):585–90. https://doi.org/10.2215/CJN.05650516 PMID: 28336816

45. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008; 371(9608):261–9. https://doi.org/10.1016/S0140-6736(08)60136-1 PMID: 18207020

46. Archie JG, Collins JS, Lebel RR. Quantitative standards for fetal and neonatal autopsy. Am J Clin Pathol. 2006; 126(2):256–65. https://doi.org/10.1309/FK9D-5WBA-1UPE-T5BB PMID: 16891202

47. Godlewski G, Gaubert-Cristol R, Rouy S, Prudhomme M. Liver development in the rat and in man during the embryonic period (Carnegie stages 11–23). Microsc Res Tech. 1997; 39(4):314–27. https://doi.org/10.1002/(SICI)1097-0029(19971115)39:4<314::AID-JEMT2>3.0.CO;2-H PMID: 9407542

48. Latini G, Gallo F, De Felice C. Birth characteristics and hepatoblastoma risk in young children. Cancer. 2004; 101(1):210. https://doi.org/10.1002/cncr.20357 PMID: 15222013

49. Erlandsson MC, Sherar LB, Baxter-Jones AD, Jackowski SA, Ludwig-Auser H, Arnold C, et al. Preterm birth and adolescent bone mineral content. Am J Perinatol. 2011; 28(2):157–63. https://doi.org/10.1055/s-0030-1263299 PMID: 20694944

50. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.

51. Jackowski SA, Erlandsson MC, Minwald RL, Faulkner RA, Bailey DA, Kontulainen SA, et al. Effect of maturation timing on bone mineral content accrual from childhood to adulthood: evidence from 15 years of longitudinal data. Bone. 2011; 48(5):1178–85. https://doi.org/10.1016/j.bone.2011.02.010 PMID: 21338727